abstract |
The invention relates to novel chemical entities that act as thromboxane (TX) A 2 receptor, or T prostanoid receptor (TP), antagonists and to their use in the treatment of human diseases in which thromboxane (TX) A 2 and of all other agents that act as incidental ligands of TP play a role. Compounds are-represented by the formula (I): n nwherein:n R 1 is selected from the group consisting of a difluoromethoxy group, a trifluoromethoxy group, a difluoromethyl group, a primary amide, a secondary amide group, a tertiary amide group, and a nitrile group; and R 2 is selected from the group consisting of an alkyl group of 6 or fewer carbons and a halogenated alkyl group of 6 or fewer carbons, wherein R 2 is not tert butyl, or a pharmaceutically acceptable salt thereof. |